Acute presentation of rheumatoid arthritis following cancer chemotherapy using the topoisomerase I inhibitor irinotecan.
Yau
Thomas C
TC
Division of Haematology/Oncology, Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong.
Chu
Kin W
KW
Mok
Mo Y
MY
Liang
Raymond H
RH
Epstein
Richard J
RJ
D000208:Acute Disease; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000139:chemically induced*; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D006801:Humans; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D059004:Topoisomerase I Inhibitors
D000972:Antineoplastic Agents, Phytogenic; D059004:Topoisomerase I Inhibitors; D000077146:Irinotecan; D002166:Camptothecin